Efficacy of garenoxacin in patients with macrolide-resistant Mycoplasma pneumoniae pneumonia
Abstract
The prevalence of macrolide-resistant Mycoplasma pneumoniae in Japan is increasing once again. The therapeutic efficacy of quinolone garenoxacin was compared with minocycline, which is recommended as the first-choice drug in patients with macrolide-resistant M. pneumoniae pneumonia. Defervescence within 48 h after initiation of antibiotics was observed in 90.6% of garenoxacin and 90% of minocycline recipients. Our results indicated that garenoxacin can be considered as the first-choice drug for the treatment of macrolide-resistant M. pneumoniae pneumonia.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.